Outcomes in Hepatitis C Positive Liver Transplantation: Timing of Direct-Acting Antiviral Treatment and Impact on Graft Fibrosis
- PMID: 34578412
- PMCID: PMC8473279
- DOI: 10.3390/v13091831
Outcomes in Hepatitis C Positive Liver Transplantation: Timing of Direct-Acting Antiviral Treatment and Impact on Graft Fibrosis
Abstract
Liver transplantation for hepatitis C virus (HCV)-related disease has the lowest five-year graft survival among all liver transplant recipients. Graft failure due to accelerated fibrosis from unrestrained HCV replication is common. Optimal timing of HCV treatment with direct-acting antiviral agents remains unknown. We compared HCV liver transplant recipients successfully treated for HCV before transplant to those treated within 1 year of transplant to determine if graft fibrosis, measured by Fib-4 scores, differs with timing of treatment. Fib-4 scores less than or equal to 1.45 defined minimal fibrosis and greater than 1.45 defined greater than minimal fibrosis. We identified 117 liver transplant recipients: 52 treated before transplantation and 65 treated within 1 year of transplantation. Overall, 34% of recipients had minimal fibrosis, and the likelihood of having minimal fibrosis following treatment and liver transplantation did not differ by timing of treatment. The odds ratio of having greater than minimal fibrosis was 0.65 (95% CI 0.30, 1.42) among those treated within 1 year after transplantation compared to those treated before transplantation (p-value 0.28). Importantly, nearly 2/3 of these patients had evidence of fibrosis progression one year after sustained virologic response, supporting recommendations for early antiviral-based treatment to prevent accumulation of HCV-related disease.
Keywords: graft fibrosis; hepatitis C Virus; liver transplant.
Conflict of interest statement
The authors declare no conflict of interest.
Figures

Similar articles
-
Progression of fibrosis in liver transplant recipients with hepatitis C before and after sustained virologic response.Clin Transplant. 2023 Oct;37(10):e15050. doi: 10.1111/ctr.15050. Epub 2023 Jun 17. Clin Transplant. 2023. PMID: 37329298
-
Relationship between the interleukin-28b gene polymorphism and the histological severity of hepatitis C virus-induced graft inflammation and the response to antiviral therapy after liver transplantation.Liver Transpl. 2011 Mar;17(3):289-98. doi: 10.1002/lt.22235. Liver Transpl. 2011. PMID: 21384511
-
Improved Graft Survival After Liver Transplantation for Recipients With Hepatitis C Virus in the Direct-Acting Antiviral Era.Liver Transpl. 2019 Apr;25(4):598-609. doi: 10.1002/lt.25424. Liver Transpl. 2019. PMID: 30716208
-
Hepatitis C virus reinfection after liver transplantation: is there a role for direct antiviral agents?World J Gastroenterol. 2014 Jul 28;20(28):9253-60. doi: 10.3748/wjg.v20.i28.9253. World J Gastroenterol. 2014. PMID: 25071318 Free PMC article. Review.
-
Concise review: Interferon-free treatment of hepatitis C virus-associated cirrhosis and liver graft infection.World J Gastroenterol. 2016 Nov 7;22(41):9044-9056. doi: 10.3748/wjg.v22.i41.9044. World J Gastroenterol. 2016. PMID: 27895394 Free PMC article. Review.
Cited by
-
Asian Pacific Association for the Study of the Liver clinical practice guidelines on liver transplantation.Hepatol Int. 2024 Apr;18(2):299-383. doi: 10.1007/s12072-023-10629-3. Epub 2024 Feb 28. Hepatol Int. 2024. PMID: 38416312
-
Revolution in the diagnosis and management of hepatitis C virus infection in current era.World J Hepatol. 2022 Apr 27;14(4):647-669. doi: 10.4254/wjh.v14.i4.647. World J Hepatol. 2022. PMID: 35646260 Free PMC article.
-
Managing HBV and HCV Infection Pre- and Post-liver Transplant.J Clin Exp Hepatol. 2024 Mar-Apr;14(2):101287. doi: 10.1016/j.jceh.2023.09.008. Epub 2023 Sep 23. J Clin Exp Hepatol. 2024. PMID: 38076445 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical